Literature DB >> 14978182

Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.

Marie-Agnès Dragon-Durey1, Véronique Frémeaux-Bacchi, Chantal Loirat, Jacques Blouin, Patrick Niaudet, Georges Deschenes, Paul Coppo, Wolf Herman Fridman, Laurence Weiss.   

Abstract

Factor H (FH) is the major regulatory protein of the complement alternative pathway, with a structure consisting of a tandem array of 20 homologous units, called short consensus repeats (SCR). Reported are 16 FH-deficient patients. Among six patients with homozygous deficiency, four presented with membranoproliferative glomerulonephritis, and two with atypical hemolytic uremic syndrome (HUS). The ten other patients had heterozygous FH deficiency and developed atypical HUS. HUS onset occurred from birth to midadulthood, and disease progression was variable. Four children with homozygous or heterozygous FH deficiency and HUS underwent renal transplantation, which was successful in three but failed as a result of recurrence of HUS in one patient. All but one patient exhibited alternative pathway-mediated complement consumption, with no detectable FH antigenic levels or with 50% immunochemical or functional FH levels in the case of complete or partial deficiency, respectively. The molecular mechanisms of the deficiency were documented in all cases by exon-specific sequencing analysis. These mechanisms included nucleotide substitutions, insertion, or deletion located in SCR 2, 7, 11, 13, 15, and 20, leading to an amino acid substitution or to a stop codon. This report emphasizes the variability in the clinical progression of kidney diseases associated with FH deficiencies. Genetic analysis reveals the molecular abnormalities associated with FH deficiencies to be polymorphous.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978182     DOI: 10.1097/01.asn.0000115702.28859.a7

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  117 in total

1.  Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.

Authors:  Elisa Gnappi; Marco Allinovi; Augusto Vaglio; Elena Bresin; Annalisa Sorosina; Francesco P Pilato; Landino Allegri; Lucio Manenti
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

2.  Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome.

Authors:  Philipp A Lang; Ortraud Beringer; Jan P Nicolay; Oliver Amon; Daniela S Kempe; Tobias Hermle; Philipp Attanasio; Ahmad Akel; Richard Schäfer; Björn Friedrich; Teut Risler; Matthias Baur; Christoph J Olbricht; Lothar Bernd Zimmerhackl; Peter F Zipfel; Thomas Wieder; Florian Lang
Journal:  J Mol Med (Berl)       Date:  2006-04-19       Impact factor: 4.599

Review 3.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

Review 4.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

5.  Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Authors:  Valérie Leroy; Véronique Fremeaux-Bacchi; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes; Marie-Alice Macher; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2010-12-25       Impact factor: 3.714

6.  Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe.

Authors:  A J Turley; B Gathmann; C Bangs; M Bradbury; S Seneviratne; L I Gonzalez-Granado; S Hackett; N Kutukculer; H Alachkar; S Hambleton; H Ritterbusch; P Kralickova; L Marodi; M G Seidel; G Dueckers; J Roesler; A Huissoon; H Baxendale; J Litzman; P D Arkwright
Journal:  J Clin Immunol       Date:  2015-02-08       Impact factor: 8.317

7.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

8.  The C-terminus of complement factor H is essential for host cell protection.

Authors:  Mihály Józsi; Martin Oppermann; John D Lambris; Peter F Zipfel
Journal:  Mol Immunol       Date:  2007-01-17       Impact factor: 4.407

Review 9.  Progress in defining the molecular biology of age related macular degeneration.

Authors:  Andrew Lotery; Dorothy Trump
Journal:  Hum Genet       Date:  2007-07-21       Impact factor: 4.132

10.  Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.

Authors:  Johannes Hofer; Andreas R Janecke; L B Zimmerhackl; Magdalena Riedl; Alejandra Rosales; Thomas Giner; Gerard Cortina; Carola J Haindl; Barbara Petzelberger; Miriam Pawlik; Verena Jeller; Udo Vester; Bettina Gadner; Michael van Husen; Michael L Moritz; Reinhard Würzner; Therese Jungraithmayr
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.